NSTL国家科技图书文献中心

1. Maintenance Therapy in AML: What Is the Future Potential? NSTL国家科技图书文献中心

Hannah Goulart | Andrew H. Wei ... - 《Acta biomaterialia》 - 2025,193 - 38～49 - 共12页

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML* and present a commentary on the future of* | ABSTRACT Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

关键词： AML | AML molecular diagnosis and therapy | chemotherapy | leukemia

2. Maintenance Therapy in AML: What Is the Future Potential? NSTL国家科技图书文献中心

Hannah Goulart | Andrew H. Wei ... - 《American Journal of Hematology》 - 2025,100(S2) - 38～49 - 共12页

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML* and present a commentary on the future of* | Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

关键词： AML; AML molecular diagnosis and therapy; chemotherapy; leukemia.

3. FYB1-targeted modulation of CAPG promotes AML progression NSTL国家科技图书文献中心

Liu, Wenyuan | Yin, Hongli ... - 《Molecular and Cellular Biochemistry》 - 2025,480(2) - 985～999 - 共15页

摘要：Acute myeloid leukemia (AML) is a rare and | differs substantially between AML* tissues and normal* | AML progression. Therefore, understanding the effect | of FYB1 on AML* could improve the success rate of* | therapeutic approaches and prognosis for patients with AML

关键词： FYB1 | CAPG | AML | Proliferation | Apoptosis | Prognosis

4. A Rare Cytogenetic Presentation of Acute Myeloid Leukemia (AML-M2) Mimicking Acute Promyelocytic Leukemia NSTL国家科技图书文献中心

Tianting Ma | Han Zhang ... - 《Clinical laboratory》 - 2025,71(2) - 352～354 - 共3页

摘要：Background: Acute* myeloid leukemia (AML) with* | diagnosis of acute* myeloid leukemia (AML-M2) was made* | specific subtype of AML* categorized as AML t(8;21) in the* | WHO classification and AML-M2 in the FAB | the t(8;21)(q22;q22) mutation, which produces the

关键词： acute myeloid leukemia, AML t(8;21), AML-M2,AML1/ETO fusion

5. Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy NSTL国家科技图书文献中心

Catherine Gutierrez ... | Anthony Stein ... - 《American Journal of Hematology》 - 2025,100(S2) - 23～37 - 共15页

摘要：Acute myeloid leukemia is a molecularly | heterogenous disease caused by the rapid expansion and | impaired differentiation of malignant myeloid progenitors | . Overall, outcomes remain poor, and more than half of | patients develop relapsed or refractory disease after

关键词： AML; acute myeloid leukemia; immunotherapies; targeted therapies.

6. Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy NSTL国家科技图书文献中心

Catherine Gutierrez ... | Anthony Stein ... - 《Acta biomaterialia》 - 2025,193 - 23～37 - 共15页

摘要：ABSTRACT Acute* myeloid leukemia is a* | molecularly heterogenous disease caused by the rapid | expansion and impaired differentiation of malignant | myeloid progenitors. Overall, outcomes remain poor, and | more than half of patients develop relapsed or

关键词： acute myeloid leukemia | AML | immunotherapies | targeted therapies

7. Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents NSTL国家科技图书文献中心

Keith W. Pratz | Harry P. Erba - 《American Journal of Hematology》 - 2025,100(S2) - 16～22 - 共7页

摘要： AML with particular molecular changes. In this | Backbone therapy for acute myeloid leukemia | for younger adults has for 50 years been based on a | combination of cytarabine and anthracycline. Over the past | 10 years the addition of several targeted agents

关键词： AML; AML‐molecular diagnosis and therapy; Acute myeloid leukemia; Induction chemotherapy

8. Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents NSTL国家科技图书文献中心

Keith W. Pratz | Harry P. Erba - 《Acta biomaterialia》 - 2025,193 - 16～22 - 共7页

摘要： subsets of AML* with particular molecular changes. In* | ABSTRACT Backbone therapy for acute myeloid | leukemia for younger adults has for 50 years been based | on a combination of cytarabine and anthracycline | . Over the past 10 years the addition of several

关键词： Acute myeloid leukemia | AML | AML‐molecular diagnosis and therapy | Induction chemotherapy | Targeted therapy

9. Acute Myeloid Leukemia with Eosinophilia (FAB AML-M4Eo) having NPM1/DNMT3A/IDH2 Gene Mutations and t(5;12)(q31;p13) NSTL国家科技图书文献中心

Xu, Xiuping | Shen, Guojian - 《Clinical laboratory》 - 2025,71(1) - 162～165 - 共4页

摘要：Background: AML-M4Eo is a type of AML | makes the classification of AML* more accurate and lays* | prognosis of AML. Methods: Blood routine and bone marrow | . AML* 96 genes test and bone marrow cytogenetic* | % eosinophilic cells, indicating AML-M4Eo. AML* gene and*

关键词： AML-M4Eo | eosinophilia | gene mutation | t(5;12)(q31; p13)

10. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All- Trans Retinoic Acid or Valproic Acid to Decitabine NSTL国家科技图书文献中心

Bresser, Helena | Schmoor, Claudia ... - 《European Journal of Haematology》 - 2025,114(2) - 231～237 - 共7页

摘要：, NCT00867672) of elderly, newly diagnosed AML* patients, ATRA* | agents appear warranted in non-M3 AML* patients* | In a randomized phase II trial (AMLSG 14-09 | combined with decitabine (DEC) significantly improved the | overall response rate (ORR) and survival also in

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML* and present a commentary on the future of* | ABSTRACT Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

关键词： AML | AML molecular diagnosis and therapy | chemotherapy | leukemia

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML* and present a commentary on the future of* | Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

关键词： AML; AML molecular diagnosis and therapy; chemotherapy; leukemia.

摘要：Acute myeloid leukemia (AML) is a rare and | differs substantially between AML* tissues and normal* | AML progression. Therefore, understanding the effect | of FYB1 on AML* could improve the success rate of* | therapeutic approaches and prognosis for patients with AML

关键词： FYB1 | CAPG | AML | Proliferation | Apoptosis | Prognosis

摘要：Background: Acute* myeloid leukemia (AML) with* | diagnosis of acute* myeloid leukemia (AML-M2) was made* | specific subtype of AML* categorized as AML t(8;21) in the* | WHO classification and AML-M2 in the FAB | the t(8;21)(q22;q22) mutation, which produces the

关键词： acute myeloid leukemia, AML t(8;21), AML-M2,AML1/ETO fusion

摘要：Acute myeloid leukemia is a molecularly | heterogenous disease caused by the rapid expansion and | impaired differentiation of malignant myeloid progenitors | . Overall, outcomes remain poor, and more than half of | patients develop relapsed or refractory disease after

关键词： AML; acute myeloid leukemia; immunotherapies; targeted therapies.

摘要：ABSTRACT Acute* myeloid leukemia is a* | molecularly heterogenous disease caused by the rapid | expansion and impaired differentiation of malignant | myeloid progenitors. Overall, outcomes remain poor, and | more than half of patients develop relapsed or

关键词： acute myeloid leukemia | AML | immunotherapies | targeted therapies

摘要： AML with particular molecular changes. In this | Backbone therapy for acute myeloid leukemia | for younger adults has for 50 years been based on a | combination of cytarabine and anthracycline. Over the past | 10 years the addition of several targeted agents

关键词： AML; AML‐molecular diagnosis and therapy; Acute myeloid leukemia; Induction chemotherapy

摘要： subsets of AML* with particular molecular changes. In* | ABSTRACT Backbone therapy for acute myeloid | leukemia for younger adults has for 50 years been based | on a combination of cytarabine and anthracycline | . Over the past 10 years the addition of several

关键词： Acute myeloid leukemia | AML | AML‐molecular diagnosis and therapy | Induction chemotherapy | Targeted therapy

摘要：Background: AML-M4Eo is a type of AML | makes the classification of AML* more accurate and lays* | prognosis of AML. Methods: Blood routine and bone marrow | . AML* 96 genes test and bone marrow cytogenetic* | % eosinophilic cells, indicating AML-M4Eo. AML* gene and*

关键词： AML-M4Eo | eosinophilia | gene mutation | t(5;12)(q31; p13)

摘要：, NCT00867672) of elderly, newly diagnosed AML* patients, ATRA* | agents appear warranted in non-M3 AML* patients* | In a randomized phase II trial (AMLSG 14-09 | combined with decitabine (DEC) significantly improved the | overall response rate (ORR) and survival also in

关键词： AML | ATRA | epigenetics | HMA | TP53

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML and present a commentary on the future of | ABSTRACT Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

关键词： AML | AML molecular diagnosis and therapy | chemotherapy | leukemia

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML and present a commentary on the future of | Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

关键词： AML; AML molecular diagnosis and therapy; chemotherapy; leukemia.

摘要：Acute myeloid leukemia (AML) is a rare and | differs substantially between AML tissues and normal | AML progression. Therefore, understanding the effect | of FYB1 on AML could improve the success rate of | therapeutic approaches and prognosis for patients with AML

关键词： FYB1 | CAPG | AML | Proliferation | Apoptosis | Prognosis

摘要：Background: Acute myeloid leukemia (AML) with | diagnosis of acute myeloid leukemia (AML-M2) was made | specific subtype of AML categorized as AML t(8;21) in the | WHO classification and AML-M2 in the FAB | the t(8;21)(q22;q22) mutation, which produces the

关键词： acute myeloid leukemia, AML t(8;21), AML-M2,AML1/ETO fusion

摘要：Acute myeloid leukemia is a molecularly | heterogenous disease caused by the rapid expansion and | impaired differentiation of malignant myeloid progenitors | . Overall, outcomes remain poor, and more than half of | patients develop relapsed or refractory disease after

关键词： AML; acute myeloid leukemia; immunotherapies; targeted therapies.

摘要：ABSTRACT Acute myeloid leukemia is a | molecularly heterogenous disease caused by the rapid | expansion and impaired differentiation of malignant | myeloid progenitors. Overall, outcomes remain poor, and | more than half of patients develop relapsed or

关键词： acute myeloid leukemia | AML | immunotherapies | targeted therapies

摘要： AML with particular molecular changes. In this | Backbone therapy for acute myeloid leukemia | for younger adults has for 50 years been based on a | combination of cytarabine and anthracycline. Over the past | 10 years the addition of several targeted agents

关键词： AML; AML‐molecular diagnosis and therapy; Acute myeloid leukemia; Induction chemotherapy

摘要： subsets of AML with particular molecular changes. In | ABSTRACT Backbone therapy for acute myeloid | leukemia for younger adults has for 50 years been based | on a combination of cytarabine and anthracycline | . Over the past 10 years the addition of several

关键词： Acute myeloid leukemia | AML | AML‐molecular diagnosis and therapy | Induction chemotherapy | Targeted therapy

摘要：Background: AML-M4Eo is a type of AML | makes the classification of AML more accurate and lays | prognosis of AML. Methods: Blood routine and bone marrow | . AML 96 genes test and bone marrow cytogenetic | % eosinophilic cells, indicating AML-M4Eo. AML gene and

关键词： AML-M4Eo | eosinophilia | gene mutation | t(5;12)(q31; p13)

摘要：, NCT00867672) of elderly, newly diagnosed AML patients, ATRA | agents appear warranted in non-M3 AML patients | In a randomized phase II trial (AMLSG 14-09 | combined with decitabine (DEC) significantly improved the | overall response rate (ORR) and survival also in

关键词： AML | ATRA | epigenetics | HMA | TP53

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML* and present a commentary on the future of* | ABSTRACT Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

摘要： acute myeloid leukemia (AML) including the addition of | strategies in AML* and present a commentary on the future of* | Over the last decade, there have been | significant advancements in the treatment for patients with | novel, targeted agents to intensive or nonintensive

摘要：Acute myeloid leukemia (AML) is a rare and | differs substantially between AML* tissues and normal* | AML progression. Therefore, understanding the effect | of FYB1 on AML* could improve the success rate of* | therapeutic approaches and prognosis for patients with AML

摘要：Background: Acute* myeloid leukemia (AML) with* | diagnosis of acute* myeloid leukemia (AML-M2) was made* | specific subtype of AML* categorized as AML t(8;21) in the* | WHO classification and AML-M2 in the FAB | the t(8;21)(q22;q22) mutation, which produces the

摘要：ABSTRACT Acute* myeloid leukemia is a* | molecularly heterogenous disease caused by the rapid | expansion and impaired differentiation of malignant | myeloid progenitors. Overall, outcomes remain poor, and | more than half of patients develop relapsed or

摘要： subsets of AML* with particular molecular changes. In* | ABSTRACT Backbone therapy for acute myeloid | leukemia for younger adults has for 50 years been based | on a combination of cytarabine and anthracycline | . Over the past 10 years the addition of several

摘要：Background: AML-M4Eo is a type of AML | makes the classification of AML* more accurate and lays* | prognosis of AML. Methods: Blood routine and bone marrow | . AML* 96 genes test and bone marrow cytogenetic* | % eosinophilic cells, indicating AML-M4Eo. AML* gene and*

摘要：, NCT00867672) of elderly, newly diagnosed AML* patients, ATRA* | agents appear warranted in non-M3 AML* patients* | In a randomized phase II trial (AMLSG 14-09 | combined with decitabine (DEC) significantly improved the | overall response rate (ORR) and survival also in